Cardiff Oncology, Inc. (CRDF)
| Market Cap | 306.79M |
| Revenue (ttm) | 365,993 |
| Net Income (ttm) | -22.60M |
| Shares Out | 20.87M |
| EPS (ttm) | -1.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $8.28 |
| Previous Close | $8.78 |
| Change ($) | -0.50 |
| Change (%) | -5.69% |
| Day's Open | 8.84 |
| Day's Range | 8.27 - 8.94 |
| Day's Volume | 534,938 |
| 52-Week Range | 0.83 - 25.50 |
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Cardiff Oncology Inc (NASDAQ: CRDF) has announced data from its ongoing Phase 1b/2 trial evaluating onvansertib combined with standard-of-care therapy in second-line KRAS-mutated metastatic colorectal c...
SAN DIEGO, April 12, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical need for new tre...
SAN DIEGO, April 10, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical need for new tre...
SAN DIEGO, April 10, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical need for new tre...
SAN DIEGO, April 8, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical need for new trea...
Cardiff Oncology (CRDF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down ...
SAN DIEGO, March 11, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment...
SAN DIEGO, March 10, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment...
SAN DIEGO, March 3, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment ...
Cardiff Oncology (CRDF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardiff Oncology Inc (NASDAQ: CRDF) has announced updated data from its Phase 2 trial evaluating the oral combination of onvansertib, Johnson & Johnson's (NYSE: JNJ) Zytiga (abiraterone), and prednisone...
This cancer specialist is looking to defeat the KRAS mutation.
Investors need to pay close attention to Cardiff Oncology (CRDF) stock based on the movements in the options market lately.
The biotech presented data from an early-stage study of its experimental colorectal cancer drug.
SAN DIEGO, Jan. 15, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing new treatment options for cancer patients in indications with the greate...
These clinical-stage drug developers were unstoppable last year.
The biopharma sector weathered the COVID-19 pandemic fairly well, with the Shares Nasdaq Biotechnology Etf (NASDAQ: IBB) outperforming the S&P 500 Index. This defensive sector also benefited from opport...
These stocks have made investors richer by posting explosive revenue growth or advancing significantly in high-impact programs.
SAN DIEGO, Dec. 21, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment ...
Biotech investors had more than just vaccines to think about this year.
SAN DIEGO, Dec. 6, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment o...
Here's why shares of these drugmakers seem unstoppable this year.
An analyst's bullish outlook sent the biotech stock soaring.
SAN DIEGO, Sept. 29, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new t...
Any time there is good news that drives a stock higher, some investors know that the companies making the news may use the strength to raise additional capital. Not all secondary offerings come on the h...
SAN DIEGO, Sept. 14, 2020 /PRNewswire/ -- Cardiff Oncology, Inc.
SAN DIEGO, Aug. 11, 2020 /PRNewswire/ -- Cardiff Oncology, Inc.
Today also marked the beginning of bank earnings season, with JPMorgan beating expectations on both earnings and revenues driven by a surge in trading revenue amid the market’s volatile second quarter. ...
As the virus spreads, if you’re looking to bet against the market or hedge, our deep learning algorithms paired with out Artificial Intelligence (“AI”) data has some Top Shorts named for you today.
About CRDF
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zyti... [Read more...]
| Industry Biotechnology | Founded 1999 |
| CEO Mark Erlander | Employees 11 |
| Stock Exchange NASDAQ | Ticker Symbol CRDF |
Financial Performance
In 2020, CRDF's revenue was $365,993, an increase of 49.61% compared to the previous year's $244,632. Losses were -$19.31 million, 17.6% more than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for CRDF stock is "Buy." The 12-month stock price forecast is 26.25, which is an increase of 217.03% from the latest price.